Canton Strategic Holdings (CNTN) EBT (2021 - 2026)
Canton Strategic Holdings' (CNTN) quarterly EBT came in at -$51.6 million in Q1 2026, down 1928.7% YoY from $2.8 million in Q1 2025, and down 279.3% on a QoQ basis from -$13.6 million in Q4 2025.
Powered by 
Analysis
Canton Strategic Holdings (CNTN) EBT (2021 - 2026) Analysis & Trends
Canton Strategic Holdings (CNTN) has 6 years of EBT data on file, last reported at -$51.6 million in Q1 2026.
- Quarterly EBT fell 1928.7% year-over-year to -$51.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$69.1 million (down 455.17% YoY) and the FY2025 annual result came in at -$42.1 million, down 245.18% from the prior year.
- EBT eased to -$51.6 million in Q1 2026, from -$13.6 million in the prior quarter.
- In the past five years, EBT ranged from a high of -$197435.0 in Q4 2022 to a low of -$51.6 million in Q1 2026.
- A 5-year average of -$5.9 million and a median of -$2.3 million in 2023 frame the typical range for EBT.
- Annual changes were most pronounced in 2022 — EBT surged 45.09% — and 2026, when it slumped 1928.7%.
- Tracing CNTN's EBT over 5 years: stood at -$197435.0 in 2022, then plunged by 1152.96% to -$2.5 million in 2023, then slumped by 53.08% to -$3.8 million in 2024, then sank by 259.0% to -$13.6 million in 2025, then tumbled by 279.3% to -$51.6 million in 2026.
- The last three EBT figures came in at -$51.6 million (Q1 2026), -$13.6 million (Q4 2025), and -$2.1 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 542.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -767.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 312.46 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 177.81 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -11.37 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - | -24.63 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -24.63 Mn |
| Mar 31, 2026 | -51.56 Mn |
| Dec 31, 2025 | -13.59 Mn |
| Sep 30, 2025 | -2.10 Mn |
| Jun 30, 2025 | -1.43 Mn |
| Mar 31, 2025 | -2.54 Mn |
| Dec 31, 2024 | -3.82 Mn |
| Sep 30, 2024 | -3.80 Mn |
| Jun 30, 2024 | -2.33 Mn |
| Mar 31, 2024 | -2.26 Mn |
| Dec 31, 2023 | -2.47 Mn |
| Sep 30, 2023 | -1.82 Mn |
| Jun 30, 2023 | -2.34 Mn |
| Mar 31, 2023 | -2.69 Mn |
| Dec 31, 2022 | -1.76 Mn |
| Sep 30, 2022 | -2.13 Mn |
| Jun 30, 2022 | -1.64 Mn |
| Mar 31, 2022 | -2.95 Mn |
| Dec 31, 2021 | -359,870.00 |
| Sep 30, 2021 | -777,113.00 |